Non-ASH Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena.

  • Caplacizumab Plus Standard Care Reduces Thromboembolic Events, Mortality in Patients with Thrombotic Thrombocytopenia Purpura Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    The standard of care for thrombotic thrombocytopenia purpura (TTP) is plasma exchange and immunosuppression, though many patients remain at risk for thrombotic complications until remission is achieved. Caplacizumab, an investigational anti-von Willebrand factor nanobody for the treatment of acquired TTP, was previously shown to shorten the time to resolution of TTP episodes, compared with placebo, […]

  • When Is it Safe for Patients with Chronic Myeloid Leukemia to Stop Tyrosine Kinase Inhibitor Treatment? Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    With the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, dasinitib, or nilotinib, patients with chronic myeloid leukemia (CML) experience longer survival and higher response rates than with previously available treatments. For certain patients who achieve a durable molecular response (MR) with TKI treatment, it may be possible to stop TKI treatment and maintain […]

  • Inotuzumab Ozogamicin Results in Longer Overall Survival Versus Standard Care for ALL Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    In an update from the ongoing phase III INO-VATE trial, treatment with inotuzumab ozogamicin prolonged overall survival (OS) and progression-free survival (PFS) in patients with relapsed/refractory acute lymphocytic leukemia (ALL), compared with standard care. Hagop Kantarjian, MD, from the University of Texas MD Anderson Cancer Center, presented the results at the European Hematology Association’s 21st […]

  • Masitinib Improves Symptom Burden, Responses in Patients with Severe Systemic Mastocytosis Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    Masitinib, a selective oral tyrosine kinase inhibitor (TKI) targeting wild-type KIT, LYN, and FYN, reduced the severity of a diverse range of symptoms in patients with severely symptomatic indolent or smoldering systemic mastocytosis (ISM or SSM) who were unresponsive to other treatments, according to results from a randomized phase III trial presented by Olivier Hermine, […]

  • POLLUX Trial: Triplet Daratumumab Combination Reduces Risk of Disease Progression in Relapsed/Refractory Myeloma Monday, August 1st, 2016 | August 2016, Volume 2, Issue 8

    Combining the anti-CD38 antibody daratumumab with lenalidomide and dexamethasone led to a lower risk of disease progression and death, compared with lenalidomide and dexamethasone alone, according to results from the phase III POLLUX trial of patients with relapsed/refractory multiple myeloma (RRMM). “Daratumumab induced deep responses when combined with standard of care, more than doubling rates […]

1 of 12
back to top